Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker APVO
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | Waqas Khatri | 69,965 | 3.7% | SCHEDULE 13G/A ↗ |
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B | 69,965 | 3.7% | SCHEDULE 13G/A ↗ |
| Nov 12, 2026 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | Ayrton Capital LLC | 69,965 | 3.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | Heights Capital Management, Inc. | 83,854 | 6.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | CVI Investments, Inc. | 83,854 | 6.3% | SCHEDULE 13G/A ↗ |
| Jun 22, 2026 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Niowave, Inc. | 151,723 | 12.2% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | Heights Capital Management, Inc. | 83,854 | 8.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | CVI Investments, Inc. | 83,854 | 8.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | Steven A. Cohen | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | Point72 Capital Advisors, Inc. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | Point72 Asset Management, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 7, 2025 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | Bank of America Corp /DE/ | 86 | 0.0% | SCHEDULE 13G/A ↗ |
| Oct 6, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Bank of America Corp /DE/ | 494,341 | 15.0% | SCHEDULE 13G ↗ |
| Sep 17, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Steven A. Cohen | 299,944 | 9.1% | SCHEDULE 13G ↗ |
| Sep 17, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Point72 Capital Advisors, Inc. | 299,944 | 9.1% | SCHEDULE 13G ↗ |
| Sep 17, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Point72 Asset Management, L.P. | 299,944 | 9.1% | SCHEDULE 13G ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | Heights Capital Management, Inc. | 357,842 | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | CVI Investments, Inc. | 357,842 | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | L1 Capital Global Opportunities Master Fund, Ltd. | 164,300 | 5.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Waqas Khatri | 358,150 | 10.0% | SCHEDULE 13G ↗ |
| Aug 13, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B | 358,150 | 10.0% | SCHEDULE 13G ↗ |
| Aug 13, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Ayrton Capital LLC | 358,150 | 10.0% | SCHEDULE 13G ↗ |
| Jul 8, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | SC-Sigma Global Partners, LP | 357,842 | 10.0% | SCHEDULE 13G ↗ |
| Jul 8, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Mark Angelo | 357,842 | 10.0% | SCHEDULE 13G ↗ |
| Jul 8, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Yaii GP II, LLC | 357,842 | 10.0% | SCHEDULE 13G ↗ |
| Jul 8, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Yaii GP, LP | 357,842 | 10.0% | SCHEDULE 13G ↗ |
| Jul 8, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Yorkville Advisors Global II, LLC | 357,842 | 10.0% | SCHEDULE 13G ↗ |
| Jul 8, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Yorkville Advisors Global, LP | 357,842 | 10.0% | SCHEDULE 13G ↗ |
| Jul 8, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | YA Global Investments II (U.S.), LP | 357,842 | 10.0% | SCHEDULE 13G ↗ |
| Jul 8, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | YA II PN, Ltd. | 357,842 | 10.0% | SCHEDULE 13G ↗ |
| Jun 25, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Intracoastal Capital LLC | 0 | 0.0% | SCHEDULE 13G ↗ |
| Jun 25, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Daniel B. Asher | 0 | 0.0% | SCHEDULE 13G ↗ |
| Jun 25, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Mitchell P. Kopin | 0 | 0.0% | SCHEDULE 13G ↗ |
| Jun 25, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Michael Bigger | 285,000 | 9.9% | SCHEDULE 13G ↗ |
| Jun 25, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Bigger Capital Fund GP, LLC | 285,000 | 9.9% | SCHEDULE 13G ↗ |
| Jun 25, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Bigger Capital Fund L P | 285,000 | 9.9% | SCHEDULE 13G ↗ |
| Jun 23, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | L1 Capital Global Opportunities Master Fund, Ltd. | 285,000 | 9.9% | SCHEDULE 13G ↗ |
| Jun 23, 2025 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | L1 Capital Global Opportunities Master Fund, Ltd. | 20,000 | 0.7% | SCHEDULE 13G/A ↗ |
| Apr 25, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | L1 Capital Global Opportunities Master Fund, Ltd. | 421,000 | 7.6% | SCHEDULE 13G ↗ |
| Apr 25, 2025 | SCHEDULE 13G/A (amended) | APVO Aptevo Therapeutics Inc. | L1 Capital Global Opportunities Master Fund, Ltd. | 277,000 | 5.0% | SCHEDULE 13G/A ↗ |
| Apr 25, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Intracoastal Capital LLC | 0 | 0.0% | SCHEDULE 13G ↗ |
| Apr 25, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Daniel B. Asher | 0 | 0.0% | SCHEDULE 13G ↗ |
| Apr 25, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Mitchell P. Kopin | 0 | 0.0% | SCHEDULE 13G ↗ |
| Apr 10, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Heights Capital Management, Inc. | 200,000 | 6.2% | SCHEDULE 13G ↗ |
| Apr 10, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | CVI Investments, Inc. | 200,000 | 6.2% | SCHEDULE 13G ↗ |
| Apr 9, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Intracoastal Capital LLC | 0 | 0.0% | SCHEDULE 13G ↗ |
| Apr 9, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Daniel B. Asher | 0 | 0.0% | SCHEDULE 13G ↗ |
| Apr 9, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Mitchell P. Kopin | 0 | 0.0% | SCHEDULE 13G ↗ |
| Apr 8, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Michael Bigger | 200,000 | 6.2% | SCHEDULE 13G ↗ |
| Apr 8, 2025 | SCHEDULE 13G | APVO Aptevo Therapeutics Inc. | Bigger Capital Fund GP, LLC | 200,000 | 6.2% | SCHEDULE 13G ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:32 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances